About
Bioimmunate is a medical device company that offers a precision blood filtering medical technology for select autoimmune diseases. The companys platform technology is initially focused on the treatment of patients with multiple sclerosis (MS). Brain damage from MS is caused by specific MS-related cells that migrate from the blood to the brain. Bioimmunate has developed unique biological filters anchored inside special particles that are able to recognize, capture, and remove these harmful cells from the patients blood before they reach the central nervous system. Bioimmunate is dedicated to improving the quality of life of patients with autoimmune diseases, seeking to provide safer, more cost-effective therapies without side effects. The companys main R&D lab is located at the BioGiv Center at the Hebrew University in Jerusalem.
Funding history · 2 rounds · $1.9M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Bioimmunate Technologies' primary focus?
- Bioimmunate Technologies is a medical device company focused on developing precision blood filtering technology for select autoimmune diseases, with an initial focus on Multiple Sclerosis (MS).
- Where is Bioimmunate Technologies' main R&D lab located?
- Bioimmunate Technologies' main R&D lab is located at the BioGiv Center at the Hebrew University in Jerusalem.
- When was Bioimmunate Technologies founded?
- Bioimmunate Technologies was founded in July 2014.
- What is the total amount of funding Bioimmunate Technologies has raised to date?
- Bioimmunate Technologies has raised a total of $1,950,000 USD across its funding rounds.
- When did Bioimmunate Technologies complete its Pre-Seed funding round?
- Bioimmunate Technologies completed a Pre-Seed funding round in October 2017, raising $950,000 USD.
- When did Bioimmunate Technologies complete its Seed funding round?
- Bioimmunate Technologies completed a Seed funding round in September 2019, raising $1,000,000 USD.
- What is the current employee count for Bioimmunate Technologies?
- Bioimmunate Technologies currently has 7 employees.
- Who is a co-founder of Bioimmunate Technologies?
- Sigalit Carmel, MD, PhD, is a co-founder of Bioimmunate Technologies.
- What is the core mechanism of Bioimmunate Technologies' platform for treating MS?
- Bioimmunate Technologies has developed unique biological filters anchored inside special particles that recognize, capture, and remove MS-related cells from a patient's blood before they reach the central nervous system.